Institutional Investors Love Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Sentiment for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) institutional sentiment increased to 1.92 in 2019 Q1. Its up 0.58, from 1.34 in 2018Q4. The ratio has improved, as 46 investment professionals opened new or increased holdings, while 24 decreased and sold their holdings in Theravance Biopharma. The investment professionals in our partner’s database now own: 33.32 million shares, down from 33.66 million shares in 2018Q4. Also, the number of investment professionals holding Theravance Biopharma in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 18 Increased: 29 New Position: 17.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $913.91 million. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

The stock increased 0.80% or $0.13 during the last trading session, reaching $16.28. About 177,563 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 17.20% since June 13, 2018 and is downtrending. It has underperformed by 21.63% the S&P500.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on August, 7. They expect $-1.22 EPS, down 60.53 % or $0.46 from last year’s $-0.76 per share. After $-1.32 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -7.58 % EPS growth.

Baupost Group Llc Ma holds 1.77% of its portfolio in Theravance Biopharma, Inc. for 9.31 million shares. Old West Investment Management Llc owns 99,866 shares or 0.82% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.48% invested in the company for 550,000 shares. The Hong Kong-based Fosun International Ltd has invested 0.15% in the stock. Nj State Employees Deferred Compensation Plan, a New Jersey-based fund reported 31,142 shares.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Ratings analysis reveals 100% of Theravance Biopharma’s analysts are positive. Out of 2 Wall Street analysts rating Theravance Biopharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $40 while the high is $55. The stock’s average target of $47.50 is 191.77% above today’s ($16.28) share price. TBPH was included in 8 notes of analysts from February 20, 2019. The firm earned “Buy” rating on Wednesday, February 20 by Cantor Fitzgerald. The company was maintained on Wednesday, February 27 by Needham. The company was maintained on Tuesday, March 12 by Cantor Fitzgerald. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Buy” rating given on Wednesday, March 20 by Cantor Fitzgerald. The company was maintained on Tuesday, February 26 by Cantor Fitzgerald.

More notable recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: which released: “Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 – PRNewswire” on May 14, 2019, also with their article: “Protagonist: After A Strong Run, Caution Is Advised – Seeking Alpha” published on March 13, 2019, published: “Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRIâ„¢ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018 – PR Newswire” on September 11, 2018. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) were released by: and their article: “Theravance Pipeline Strong, Plans Yupelri Launch by Year End – Nasdaq” published on November 29, 2018 as well as‘s news article titled: “The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice – Benzinga” with publication date: May 24, 2019.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.